History

Founded in 2010 with a vision to bring centralized lab quality results to the point of care, Talis has evolved from university and grant funded research initiative to the public company we are today.

2021

July 2021

Talis opens 26,432 square feet lab, office and chemical storage location at Fulton Labs in Chicago’s West Loop

February 2021

Talis begins trading on The Nasdaq Global Market on February 12, 2021, under the ticker symbol TLIS

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2020

July 2020

Talis awarded $25M NIH RADX contract to launch Talis One™ system for point-of-care COVID-19 testing

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2018

May 2018

Talis awarded $4.4M by CARB-X to fund development of rapid point-of-care diagnostic tests for pathogen identification and antibiotic susceptibility

February 2018

SlipChip changes company name to Talis Biomedical and establishes headquarters in Menlo Park, California

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

2010

March 2010

Talis is founded under the company’s original name, SlipChip by Brian Coe and Rustem F. Ismagilov, Ph.D.

[bold_timeline_item_button title=”Expand” style=”” shape=”” color=”” size=”inline” url=”#” el_class=”bold_timeline_group_button”]

Our Company

Built on a foundation of world-class science and engineering, Talis is dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care. We strive to create deliver excellence in diagnostics to help combat the spread of infectious disease.

Learn More

Opportunity Awaits

If you are an exceptional scientist, engineer, or businessperson who wants to work in an exciting and collaborative environment, we want to hear from you!

Learn More